Johnson & Johnson vs Kymera Therapeutics, Inc. — Stock Comparison
Q·Score Breakdown
7.1
Bullish
Overall
5.8
Neutral
Quality
Health
Growth
Valuation
Sentiment
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
KYMR
96% of 23 covering analysts have a positive rating.
⚠ low return on equity (-27%).
Analyst Consensus
BUY
Target $252.42 (+11.1%)
24 analysts
BUY
Target $118.86 (+47.3%)
21 analysts
Fundamentals
JNJ
KYMR
26.3×
Trailing P/E
—
17.9×
Forward P/E
-19.9×
21.8%
Profit Margin
0.0%
68.0%
Gross Margin
0.0%
26.4%
ROE
-27.1%
9.9%
Revenue Growth
55.5%
-52.9%
Earnings Growth
—
0.33
Beta
—
—
Price / Book
—
$546.9B
Market Cap
$6.6B
$146 – $252
52-Week Range
$28 – $103
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →